Armata Pharmaceuticals FY2024 EPS Lifted by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Equities research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Armata Pharmaceuticals in a report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.95) per share for the year, up from their previous estimate of ($1.02). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Armata Pharmaceuticals' current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals' Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.70) EPS.

Armata Pharmaceuticals Price Performance

Shares of NYSEAMERICAN:ARMP traded down $0.07 during trading on Monday, hitting $2.34. 4,534 shares of the company were exchanged, compared to its average volume of 12,307. Armata Pharmaceuticals has a 52-week low of $1.93 and a 52-week high of $4.48. The company has a market cap of $84.66 million, a P/E ratio of -1.47 and a beta of 0.80.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.